Artiva Biotherapeutics, Inc. Common Stock (ARTV) Form 3 Artiva Biotherapeutics / Fred Aslan ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/18/2024

3. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President and CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	04/02/2033	Common Stock	257,319	5.01	D
Employee Stock Option (Right to Buy)	(2)	04/02/2033	Common Stock	51,463	5.01	D
Employee Stock Option (Right to Buy)	(3)	04/02/2033	Common Stock	100,577	5.01	D
Employee Stock Option (Right to Buy)	(4)	01/23/2034	Common Stock	26,450	5.18	D
Employee Stock Option (Right to Buy)	(5)	05/01/2034	Common Stock	113,999	13.47	D

Explanation of Responses:

1. 25% of the shares vested on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

2. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

3. 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

4. Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.

5. 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Jennifer Bush, Attorney-in-Fact	07/18/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.